Canaccord Genuity Group Initiates Coverage on CeriBell (NASDAQ:CBLL)

Equities researchers at Canaccord Genuity Group initiated coverage on shares of CeriBell (NASDAQ:CBLL) in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Canaccord Genuity Group’s price target indicates a potential upside of 7.99% from the stock’s previous close.

A number of other analysts have also commented on the stock. Bank of America initiated coverage on shares of CeriBell in a research note on Tuesday. They set a “buy” rating and a $32.00 price target for the company. Canaccord Genuity Group started coverage on shares of CeriBell in a report on Tuesday. They issued a “buy” rating and a $30.00 target price on the stock. TD Cowen started coverage on CeriBell in a research note on Tuesday. They set a “buy” rating and a $31.00 price target for the company. William Blair assumed coverage on CeriBell in a research note on Tuesday. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. assumed coverage on CeriBell in a research report on Tuesday. They set an “overweight” rating and a $32.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, CeriBell presently has a consensus rating of “Buy” and a consensus target price of $31.00.

CeriBell Stock Up 3.0 %

Shares of CeriBell stock opened at $27.78 on Tuesday. CeriBell has a 52 week low of $23.00 and a 52 week high of $28.94.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.